Connect Biopharma Holdings Limited (CNTB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.4000

-0.1900

(-11.95%)

At close: 04:00PM EDT

1.4500

+0.05

(+3.57%)

After hours:

06:04PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	1.5900
Open	1.5300
Bid	1.4000 x 900
Ask	1.4700 x 2900
Day's Range	1.2700 - 1.5750
52 Week Range	0.5570 - 26.4100
Volume	508,509
Avg. Volume	433,716

Market Cap	77.022M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-3.7370
Earnings Date	Mar 31, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.16

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CNTB

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Connect Biopharma Holdings Limi
Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
Rating
Fair Value
Economic Moat
3 days agoArgus Research

All

Simply Wall St.
Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
  Simply Wall St.
- We're Not Very Worried About Nickel Creek Platinum's (TSE:NCP) Cash Burn Rate
  Simply Wall St.
Benzinga
Connect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This Year
The Center for Drug Evaluation of the National Medical Products Administration in China has signed off Connect Biopharma Holdings Limited's (NASDAQ: CNTB) primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 in atopic dermatitis. The company will analyze data from the Stage 1 16-week treatment period based on CBP-201 on 255 patients. As a result, Connect Biopharma plans to report this trial's top-line results by year-end, earlier than initially planned. Also Read:
GlobeNewswire
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and TAICANG, SUZHOU, China, July 11, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”) today announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary anal